<DOC>
	<DOCNO>NCT00005939</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy radiation damage tumor cell . Brachytherapy use radioactive material place directly near tumor . Brachytherapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness brachytherapy treat patient recurrent prostate cancer respond standard therapy .</brief_summary>
	<brief_title>Brachytherapy Treating Patients With Recurrent Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine dosimetry toxicity interstitial colloidal phosphorus P32 ( cP32 ) patient locally recurrent prostate cancer fail conventional therapy . II . Determine maximum tolerate dose interstitial cP32 combine interstitial macroaggregated albumin ( infusional brachytherapy ) patient . III . Determine therapeutic response rate acceptable single dos cP32 patient . OUTLINE : This dose escalation study colloidal phosphorus P32 ( cP32 ) . Patients receive cP32 macroaggregated albumin via interstitial infusion use ultrasound localization . Cohorts 3 patient receive escalate dos cP32 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 4 patient experience dose limit toxicity . Additional patient treat MTD . Patients follow 1 , 2 , 4 , 6 week ; 2 , 4 , 8 , 12 , 16 , 20 , 24 month ; every 6 month thereafter death . PROJECTED ACCRUAL : A total 20-25 patient accrued phase I study total 40 patient accrue phase II study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove locally recurrent prostate cancer fail conventional therapy ( i.e. , external beam radiotherapy , radioactive seed implant , hormonal therapy ) Must confirm clinically elevate PSA and/or ultrasound Prostates 25 cm diameter ( i.e. , volume 465 cm3 ) prefer Prostates great 5 cm allow , 2 needle require good distribution study drug No clinical/radiographic evidence metastatic disease No history injury urethra , bladder , rectum PATIENT CHARACTERISTICS : Age : 21 Performance status : Not specify Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Neutrophil count least 1,900/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL ( transfusion allow ) Hepatic : Not specify Renal : Blood urea nitrogen great 25 mg/dL Creatinine great 1.5 mg/dL PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics Surgery : Not specify</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2001</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>